On July 17, 2026, the European Commission issued Regulation (EU) 2026/1289, setting downward adjustments to the maximum use levels of nine amino acid-based food additives, including glycine, L-cysteine, and L-leucine, in infant formula and foods for special medical purposes, and clearly stating that it will apply directly from October 1, 2026. For the industry, this is not merely a one-time adjustment to formulation parameters; it is more directly tied to amino acid raw material supply for the EU market, exports of reprocessed products, updates to import compliance declarations, and label filing alignment. Relevant enterprises need to quickly convert the regulatory changes into actionable compliance measures.

The newly clarified core points

According to the information provided, the European Commission issued Regulation (EU) 2026/1289 on July 17, 2026, involving nine amino acid-based food additives, including glycine, L-cysteine, and L-leucine. The regulation imposes mandatory downward adjustments to the maximum use levels of the relevant substances in infant formula and foods for special medical purposes.

At the same time, the regulation clearly states that it will apply directly from October 1, 2026. This means that once the products concerned enter the effective date, they must be handled in compliance with the new limit requirements.

The available information also indicates that this standard will affect Chinese suppliers of amino acid raw materials and reprocessed products that export to the EU, and importers will also need to update product compliance declarations and label filings accordingly.

Which positions are affected first in the export chain

Raw material supply for the EU market

From an industry perspective, enterprises directly exporting amino acid raw materials to the EU will be the first to be affected, because the regulatory changes directly point to the maximum use levels of specific amino acid-based food additives. For such enterprises, the impact is mainly reflected in external sales materials, product application scenario descriptions, and technical confirmation steps with customers, especially the compliance applicability of their raw materials in infant formula and foods for special medical purposes.

Reprocessed products and manufacturing links

For enterprises producing reprocessed products or involved in related manufacturing, the impact is more likely to be concentrated in formulation correspondence and consistency of delivery documents. Since the new regulation is a downward adjustment of maximum use levels, relevant enterprises need to focus on checking whether existing products still meet the requirements of EU customers, and whether there are any alignment issues between existing labels, technical documents, specification sheets, and the new regulation.

Importers and compliance alignment roles

It has already been clearly stated in the facts that importers must update product compliance declarations and label filings in step. Therefore, for business personnel responsible for procurement as well as law, registration, and label management, the point of impact is not only purchasing itself, but also document updates, filing path adjustments, and information synchronization efficiency with suppliers.

Supply chain coordination and delivery management

As can be observed, positions related to supply chain services and delivery management also need attention, because the effective date of the regulation has already been clearly defined. For projects that are still in execution, in production, in shipment, or waiting for filing alignment, whether the business rhythm can match the October 1, 2026 timeline will become one of the key practical issues.

Several practical actions that now need to be implemented

First check the affected product categories and applicable markets

Enterprises first need to clarify the scope of affected products, especially those involving glycine, L-cysteine, L-leucine, and the other nine amino acid-based food additives, and determine whether they are used in businesses related to infant formula or foods for special medical purposes. The key here is not only to look at the product names, but also to determine whether the specific export markets and end-use directions fall within the scope covered by the new regulation.

Synchronize compliance declarations and label materials

According to the information provided, importers need to update product compliance declarations and label filings. For export enterprises, what is more worth attention at present is whether the data alignment with importers is timely, including whether the current version of documents needs to be adjusted, whether the declaration wording required by customers has changed, and whether label-related information needs synchronized updates.

Incorporate the effective date into order and delivery arrangements

The new regulation will apply directly from October 1, 2026, which makes time management a practical issue. Analysis shows that enterprises need to pay attention to whether in-transit orders, goods to be shipped, and projects under draft contract will cross the effective date, and accordingly confirm document versions, applicable standards, and delivery requirements with customers to avoid a disconnect between business execution and regulatory applicability timing.

Keep following official statements and customer feedback

During the implementation of this type of regulation, enterprises cannot stop at the summary level. What should be paid attention to now is whether the specific wording of the regulatory text, customer requirements for compliance supporting materials, and the actual execution path of label filings in the import process will be further refined. The key here is continuous verification, not preset conclusions.

This looks more like an immediate compliance signal

From analysis, this piece of information is more suitable to be understood as a compliance change that has already entered the execution preparation stage, rather than remaining at the level of directional policy discussion. The reason is that the regulation number, release date, and direct application date are all clear, and the affected targets have already been identified as Chinese suppliers of amino acid raw materials and reprocessed products exported to the EU, as well as importers that need to update declarations and label filings.

However, it should still be distinguished that “the regulation is now clear” is not the same as “the business adjustment is already complete.” The regulation itself has already established clear requirements, but different enterprises may still differ in the implementation progress of product scope identification, customer communication, document updates, and delivery arrangements. Therefore, this is both a clear result and an industry dynamic that still needs continuous tracking and detailed execution.

From short-term adjustment to long-term requirements

Taken together, the EU’s downward adjustment of the limit values for nine amino acid-based food additives will, in the short term, first create pressure for export compliance and data updates, directly affecting supply, import, and filing links in the related business chain for infant formula and foods for special medical purposes.

A more appropriate understanding is that this is not merely a news change, but a rule adjustment with a clear effective date and practical execution requirements. For relevant enterprises, the current priority is not a generalized judgment of impact magnitude, but to quickly confirm the affected products, sort out compliance documents, connect with importer requirements, and continue to pay attention to whether further clear information emerges in subsequent execution pathways.

Basis of this article and direction for follow-up verification

This article is generated based on the user-provided news title, event occurrence time, and event summary. The information used includes: on July 17, 2026, the European Commission issued Regulation (EU) 2026/1289, imposing mandatory downward adjustments to the maximum use levels of nine amino acid-based food additives, including glycine, L-cysteine, and L-leucine, in infant formula and foods for special medical purposes; the new regulation will apply directly from October 1, 2026; this standard affects Chinese suppliers of amino acid raw materials and reprocessed products exported to the EU, and importers must update product compliance declarations and label filings.

According to the general verification path for this type of industry information, follow-up usually still needs to be cross-checked with official announcements, standards organization documents, company announcements, industry association information, and reports from authoritative media. Since the input information did not provide a specific official source link, this article does not further display the original regulation text link. Follow-up still needs to continue verification around the formal wording of the regulation, the scope of applicable product categories, and the execution path for label filings.